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Abstract Rat androgen receptor (rAR) mutants devoid of the
amino-terminal transactivation domain are able to behave as
dominant negative regulators of wild-type rAR. To address the
underlying mechanisms of the trans-dominant negative action, we
have examined the roles of the DNA-binding domain (DBD) and
the ligand-binding domain (LBD) in this process. Transactivation
experiments in CV-1 cells complemented by electrophoretic
mobility shift assays revealed that the dominant negative
receptor forms repress the function of wild-type rAR mainly
through heterodimer formation, rather than through competition
for binding to cognate DNA elements. Heterodimerization of
receptor forms containing LBDs may take place even in the
absence of specific DNA binding.
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1. Introduction
Androgen receptor (AR) is a ligand-inducible transactivat-
ing protein that regulates the di¡erentiation, development and
maintenance of male reproductive functions, in addition to
supporting sexually dimorphic functions of non-reproductive
tissues [1]. AR is a member of the nuclear receptor superfam-
ily that comprises receptors for steroids, thyroid hormones
and retinoids [2,3]. Nuclear receptors have three major func-
tional regions: an amino-terminal transactivation domain
(TAD), a central domain for DNA binding (DBD) composed
of two zinc ¢nger motifs, and a carboxyl-terminal domain for
ligand binding (LBD). By and large, nuclear receptors bind to
DNA as dimeric proteins. Loss of function in any of the three
AR domains may generate a receptor form that exhibits no
transcriptional activity but attenuates the function of wild-
type protein, i.e. the mutant receptor possesses dominant neg-
ative activity. In the case of human thyroid hormone recep-
tors, many naturally occurring, functionally de¢cient receptor
forms have been reported to be capable of repressing the
function of their normal counterparts in a trans-dominant
negative fashion, which results in resistance to thyroid hor-
mone (RTH) syndrome [4^6]. In most patients, the mutations
leading to RTH are located outside the dimerization interface
of the thyroid hormone receptor L, implying that receptor
heterodimerization plays an important role in this context
[4^6]. Potentially dominant negative forms of estrogen recep-
tors may have some bearing on the progression of breast
cancer [7].
We have previously shown that transcriptionally inactive
rat AR mutants devoid of the main activation function 1
(AF1) region located in TAD can behave as dominant nega-
tive regulators of the transactivation elicited by the wild-type
protein [8]. In this study, the underlying mechanism was ex-
amined in more detail by using a constitutively active rAR
lacking the LBD and a double mutant, rARv46^408/C562G,
devoid of TAD and de¢cient in DNA binding due to an
amino acid substitution in the DBD. Our results show that
heterodimerization, rather than competition for DNA bind-
ing, is mainly responsible for the dominant negative behavior
of rAR forms devoid of TAD. The rARv46^408/C562G mu-
tant inhibited the transactivation function of wild-type rAR
more strongly than that of an LBD-de¢cient, constitutively
active rAR form, indicating that LBD plays a role also in
androgen receptor dimerization.
2. Materials and methods
2.1. Expression vectors and other materials
pARE2tk-CAT contains two copies of the rat tyrosine aminotrans-
ferase (TAT) gene androgen response elements (AREs) inserted up-
stream of the thymidine kinase (tk) promoter driving the bacterial
chloramphenicol acetyltransferase (CAT) gene. The cryptic AP-1 site
was deleted from the vector backbone of this construct [9]. The L-
galactosidase (L-gal) expression plasmid pSVL-gal was obtained from
Promega (Madison, WI, USA). Rat AR expression vector pSGrAR
and the deletion mutant vectors pSGrARv46^408 and pSGrARv641^
902 (numbers refer to the ¢rst and the last amino acid deleted) and the
double mutant vector pSGrARv46^408/C562G were constructed as
previously described [8,10,11]. Testosterone was obtained from Makor
Chemicals, Ltd. (Jerusalem, Israel). Restriction endonucleases and
DNA-modifying enzymes were purchased from Pharmacia Biotech
(Uppsala, Sweden). [3H]Acetyl-coenzyme A was obtained from New
England Nuclear (Boston, MA, USA). Anti-receptor antiserum raised
against AR peptide 3 corresponding to residues 14^32 of rAR has
been described previously [12].
2.2. Cell culture and transfections
CV-1 and COS-1 cells (from ATCC) were maintained in Dulbecco’s
minimal essential medium containing penicillin (25 U/ml), streptomy-
cin (25 U/ml), and 10% (v/v) fetal bovine serum (FBS). Cells were
transfected using the calcium phosphate precipitation method as de-
scribed previously [8,13]. In short, the cells (1.5U106) were plated on
a 10-cm dish 24 h before adding the precipitate with indicated
amounts of expression and reporter vectors. L-Galactosidase expres-
sion plasmid, pSVL-gal (4 Wg/10-cm plate), was used as an internal
control for transfection e⁄ciency. For the preparation of whole cell
extracts, indicated amounts of expression vectors/10-cm dish were
transfected by electroporation into COS-1 cells [13]. An electrical
discharge was applied by a Bio-Rad Gene Pulser Transfection Appa-
ratus (settings: 300 V and 500 WF). Eighteen hours after transfection,
the medium was changed to one containing charcoal-stripped 2% (v/v)
FBS in the presence or absence of androgen. CAT and L-gal activities
were assayed as described [8,14,15]. Protein concentration was deter-
mined using Bio-Rad reagents according to the manufacturer’s in-
structions. Statistical analyses of the data were carried out using
two-tailed Student’s t-test.
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2.3. Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) with whole cell ex-
tracts was carried out as previously described [12,13]. Harvested cells
were resuspended in a bu¡er containing 400 mM KCl, 1 mM EDTA,
15% glycerol, 10 mM Na-phosphate (pH 7.4), 0.5 mM dithiothreitol,
1 mM phenylmethylsulfonyl £uoride, 2 Wg/ml aprotinin, 1 Wg/ml anti-
pain and 5 Wg/ml leupeptin. Cells were lysed by ¢ve cycles of freeze-
thaw (freezing in liquid nitrogen and brief thawing in 10‡C water
bath). Cell lysates were centrifuged at 16 000Ug for 30 min. Fifteen
Wg cell extract were used per assay.
2.4. Immunoblotting
Whole cell extracts from COS-1 cells were resolved by electropho-
resis on polyacrylamide gels under denaturing conditions. Proteins
were transferred onto Immobilon-P membrane (Millipore, Bedford,
MA, USA) and processed as previously described [8].
3. Results
We have previously shown that coexpression of an excess of
the deletion mutants rARv46^408 (Fig. 1A) and rARv38^
296, which lack large parts of the amino-terminal region of
rAR, abolished almost completely the transactivation elicited
by the native androgen receptor, at least in part through for-
mation of receptor heterodimers [8]. These experiments could
not, however, distinguish between the formation of function-
ally inactive AR heterodimers prior to or after the interaction
with speci¢c DNA elements. To determine more precisely the
mechanism by which this dominant negative function is ex-
erted, interference of the rARv46^408/C562G mutant with the
function of wild-type rAR and a constitutively active rAR
form (rARv641^902), devoid of the ligand-binding domain
(LBD), was studied. The rARv46^408/C562G mutant, in
which the fourth cysteine (Cys562) in the ¢rst zinc ¢nger is
converted to a glycine, does not bind to androgen response
elements (AREs) either in vitro or in vivo, as judged by
EMSA experiments and promoter interference assays, and
has no transcriptional activity of its own (see Fig. 2, Palvimo,
J.J., unpublished observations) [16]. Coexpression of a 10-fold
excess of rARv46^408/C562G attenuated transcriptional ac-
tivity of the native receptor almost completely in CV-1 cells
(Fig. 1B) and thus behaved as a negative regulator almost as
e⁄ciently as rARv46^408 that binds to DNA with high a⁄n-
ity [8,12,16]. The same 10-fold excess of rARv46^408/C562G
suppressed the function of rARv641^902, which lacks the
LBD, only by one-third (Fig. 1). This relatively minor e¡ect
was dependent on the conformation of the LBD, as ligand-
free rARv46^408/C562G (TEST ^) did not in£uence the ac-
tivity of rARv641^902 at all (Fig. 1C, black bars). It is of
further note that the receptor form rARC562G with an intact
transactivation domain (TAD, Fig. 1A) did not act as a re-
pressor in our assays (data not shown), implying that im-
paired activation function 1 (AF1) residing in the amino-ter-
minal region of rAR is important in the generation of trans-
dominant behavior.
To address the underlying mechanisms of the dominant
negative behavior in more detail, transfection studies were
complemented by EMSA experiments. Native rAR and
rARv641^902 proteins were expressed alone or together
with the dominant negative mutants rARv46^408/C562G or
rARv46^408 in COS-1 cells. Immunoblot analysis of the cell
extracts revealed that expression of either rARv46^408/
C562G or rARv46^408 did not modify dramatically the ex-
pression of transcriptionally active rAR forms, at least not to
such an extent as to explain the resulting dominant negative
action (Fig. 2A). All receptor forms with intact DNA-binding
domains (DBDs) formed speci¢c complexes with ARE as re-
vealed by EMSA (Fig. 2B, lanes 2, 3, and 5). The ARE-
rARv46^408 complexes migrated clearly faster than AREs
complexed with native rAR. A new retarded complex of in-
termediate mobility was observed, when the native and
rARv46^408 receptor forms were coexpressed (Fig. 2B, lanes
6 and 7). Heterodimer formation on hormone response ele-
ments was dependent on the integrity of the DBD of the
dominant negative rAR, as the DNA-binding-de¢cient
rARv46^408/C562G mutant failed both to bind to ARE
and to form heterodimers that were detectable by EMSA
analysis (Fig. 2B, lanes 4, 8, and 9). It is of particular note,
however, that cotransfection of native rAR with a 4-fold ex-
cess of rARv46^408/C562G abolished the formation of ARE-
native rAR complexes. By contrast, rARv46^408/C562G was
not able to perturb signi¢cantly the interaction by the LBD-
de¢cient rARv641^902 with AREs, which, in agreement with
the transactivation data, speaks for an important role of the
LBD in the heterodimer formation.
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Fig. 1. In£uence of the rARv46^408/C562G mutant on the function
of wild-type rAR and a constitutively active rAR form (rARv641^
902). A: Schematic structures of rAR forms relevant to this work.
Abbreviations: TAD, transactivation domain; DBD, DNA-binding
domain; and LBD, ligand-binding domain. The ability of the recep-
tor forms to interact with speci¢c DNA elements (AREs) is depicted
by + and 3 signs. B: In£uence of rARv46^408/C562G on the func-
tion of the native androgen receptor. C: Modulation of the function
of rARv641^902 by rARv46^408/C562G in the presence (+) and
absence (3) of androgen. Transactivation ability of the native and
constitutively active rAR forms was examined by coexpressing 1^10-
fold excess of the rARv46^408/C562G mutant (0.2^2 Wg of DNA)
in a transient expression system. Testosterone (TEST, 10 nM) was
included in the culture medium when indicated. Mean þ S.E.M. val-
ues for a minimum of three separate experiments are shown. Re-
porter gene (pARE2tk-CAT) activities are normalized by pSVL-gal
activity and expressed relative to that of wild-type rAR (B) or
rARv641^902 (C) in the absence of cotransfected rARv46^408/
C562G (= 100, shown as the shaded bar in both panels).
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4. Discussion
The dominant negative action of mutant nuclear receptors
on their wild-type counterparts is potentially mediated by at
least three di¡erent mechanisms, which need not be mutually
exclusive: (i) formation of transcriptionally inactive receptor
heterodimers; (ii) competition for binding to a cognate DNA
element; and (iii) titration of transcriptional coactivators
present in limiting amounts in nuclei [17]. Comparison of
the trans-dominant activity of the rARv46^408 mutant devoid
of AF1 in the amino-terminal region to a corresponding mu-
tant with no speci¢c DNA binding activity (rARv46^408/
C562G) demonstrated that, in the case of wild-type rAR,
heterodimer formation appears to su⁄ce for the dominant
negative action. Transactivation assays along with EMSA ex-
periments indicated indeed that dominant negative rAR forms
repress the function of native rAR mainly through hetero-
dimer formation ^ possibly already in solution ^ rather than
through direct competition for binding to AREs. In our pre-
vious experiments, AR mutants were shown to attenuate also
the function of the glucocorticoid receptor (GR) [18]. In this
latter case, however, competition for interaction with shared
hormone response elements, that is DNA binding, as opposed
to AR-GR heterodimer formation appeared to play a princi-
pal role.
There are other examples to indicate that heterodimeriza-
tion of steroid receptors may occur even in the absence of
speci¢c DNA binding. In the case of human progesterone
receptor (hPR), it has been shown that this receptor’s A
form (hPR-A), when it is otherwise transcriptionally inactive
for context-dependent reasons, may act as a trans-dominant
negative regulator of transcription that is activated by the B
form of hPR [19]. The trans-dominant action of hPR-A could
also be observed by using a hPR-A mutant de¢cient in DNA
binding [19], suggesting that, similar to our ¢ndings on rAR in
this work, the inhibitory function of hPR-A does not neces-
sarily require DNA binding.
A 10-fold excess of the mutant rARv46^408/C562G, an
amount that was su⁄cient to abolish almost completely the
function of native rAR, suppressed the activity of the LBD-
de¢cient rAR form (rARv641^902) only weakly (Fig. 1B,C).
A likely reason for this marked di¡erence in sensitivity is that
the LBD is needed for homo- or heterodimerization of rAR
proteins to occur in solution. In keeping with results from
transactivation studies, EMSA experiments revealed that
rARv46^408/C562G did not in£uence the binding of
rARv641^902 to ARE. Although the major determinants
for dimer formation of AR lie in the second zinc ¢nger of
the DBD [12], the results of this study indicate that LBD also
plays a role in (hetero)dimerization of the androgen receptor.
Taken together, these and previous ¢ndings [8,12,16,18]
demonstrate that, by taking advantage of the trans-dominant
negative behavior of selected AR forms, it should be possible
to develop expression vectors aimed at speci¢c elimination of
androgen action in intact cells. By targeting to speci¢c tissues,
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Fig. 2. Immunoblot and electrophoretic mobility shift analyses of
rAR forms coexpressed in COS-1 cells. A: Immunoblot analysis of
native rAR and its mutants coexpressed in COS-1 cells. Indicated
amounts of wild-type and mutant rAR expression vector DNA (in
Wg) were transfected by electroporation into COS-1 cells. Cells were
cultured for 30 h in the presence of 10 nM testosterone. Whole cell
extracts were prepared and immunoblot analysis was performed as
described in Section 2. Rabbit antiserum raised against a synthetic
peptide corresponding to amino acid residues 14^32 of rAR (ARp3)
was used. Each lane contained 15 Wg protein. Weakly stained bands
smaller than native rAR (molecular size V110 kDa) may originate
from proteolytic fragmentation of the receptor. AR deletion mutants
rARv46^408 and rARv46^408/C562G migrate as double bands at
V60 kDa, and the apparent molecular size of rARv641^902 is
V70 kDa. B: Detection of receptor homo- and heterodimers by
EMSA using cell extracts from the same experiment as in the immu-
noblot analysis. The samples (15 Wg protein) were incubated with
double-stranded 32P-labeled C3(1)-ARE oligomer before separating
protein-bound from free oligonucleotide by gel electrophoresis under
non-denaturing conditions. Symbols: bb, homodimeric rAR-ARE
complex; RR, homodimeric rARv46^408-ARE complex; Rb, het-
erodimeric rAR-rARv46^408-ARE complex. Asterisk depicts non-
speci¢c complexes. In addition, a weak band seen in all lanes (e.g.
lanes 4 and 9) represents non-speci¢c binding of the [32P]ARE oli-
gonucleotide to an unknown macromolecule.
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these trans-dominant negative androgen receptors may be
used as alternative means to knock-out AR function, for ex-
ample, as a novel therapeutic modality for prostate cancer.
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